Вакцинология. Учебники

1. Гендон Ю. З. Вирусные мукозальные вацины. Вопр. вирусол. 1999, 3: 100 – 105.

2. Alexandrova G., Polezhaev F., Budilovsky G. et al. Recombinant coladapted a attenuated influenza A vaccines for use in children: reactogenic to and antigenic activity of cold-adapted recombinants and analysis of isolates from the vaccines. Infect. Immun. 1984, 44: 734 – 739.

3. BaconA., Makin J., Sizer P. et al. Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Ibid. 2000, 68: 5764 – 5770.

4. Barackman J., Ott G., Pine S. et al. Oral administration of influenza vaccines in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization. Clin. Diagnost. Lab. Immunol. 2000,8:652 – 657.

5. Belshe R., Mendelman P., Treanor M. et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. New Engl. J. 1998, 338: 1405 – 1412.

6. Bergquist C., Lagergard Т., Lindblad M. et al. Local and systemic antibody responses to dextran-cholera toxin В subunit conjugates. Infect. Immun. 1995, 63: 2021 – 2025.

7. Beyer W., Palache A., de Jong J. et al. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine. 2002, 20: 1340 – 1353.

8. Boyce Т., Hsu H., Sannella E. et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasaly to healthy adults. Ibid. 2000, 15: 217 – 226.

9. Bryant M., Brown P., Gurvich N. et al. Comparison of the clearance of radiolabelled nose drops and nasal spray as mucosally delivered vaccines. Nucl. Med. Commun. 1999, 20: 171 – 174.

10. Couch R., Quarles J., Cate T. et al. Clinical trials with live cold-reas sortant influenza vaccines. Options for the Control of Influenza. New York, 1986, p. 223 – 241.

11. Davis S., Ilium L., Gill J. et al. Polymer lamellar particles as a novel adjuvant for influenza vaccines. Options for the Control of Influenza IV. Crete, Hersonissos, 2000, Abstr. W62 – 1, p. 50.

12. De Haan L., Verweij W., Fell I. et al. Role of G m1 -binding in the mucosal immunogenicity and adjuvant activity of the E.coli heat-labile enterotoxin and its В subunit. Immunology. 1998,94:424 – 430.

13. De Haan L., Willem R., Holtrop M. et al. Nasal or intramuscular immunization of mice with influenza subunit antigen and the В subunit of E.coli heat-labile toxin induces IgA- or IgG-mediated protective mucosall immunity. Vaccine. 2001, 19:2898 – 2907.

14. Del Guidece G. Toxin mutants as strong and safe adjuvants for mucosal vaccination. Options for the Control of influenza IV. Crete, Hersonissos. Abstr, W72 – 7, p. 62.

15. Douce G., Turcotte C., Cropley I. et al. Mutants of E.coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl. Acad. Sci. USA. 1995, 92: 1644 – 1648.

16. Douce G., Guiliani M., Giannelli V. et al. Mucosal immunogenicity of genetically detoxified derivates of heat-labile toxin from E.coli. Vaccine. 1998, 16: 1065 – 1073.

17. Ghendon Y. The immune response to influenza infection. Acta Virol. 1990, 34: 295 – 304.

18. Gliick U., Gebbers J., Gliick R. Phase I evaluation of intranasal virosomal influenza vaccine with and without E.coli heat-labile toxin in adult volunteers. J. Virol. 1999, 73: 7780 – 7786.

19. Gluck R. Preclinical and clinical evaluation of a new virosomal intranasal influenza vaccine. Options for the Control of Influenza IV. A.Osterhaus, N.Cox, A.Hampson (ed.). Excerpta Med. 2001, p. 969 – 978.

20. Guy B., Pascal N., Franc on A. et al. Desigh, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine. 2001, 19: 1794 – 1805.

21. Hashigucci K. Ogawa H., Ishidate T. et al. Antibody responses in volunteers induced by nasal influenza vaccine combined with E.coli heat- labile enterotoxin В subunit containing a trace amount of holotoxin. Ibid. 1996, 14: 113 -119.

22. Hashigucci K., Tamura S., Kurata T. et al. Efficacy of nasal influenza vaccine combined with E.coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin in healthy volunteers. J. Jpn. Assoc. Infect. Dis. 1997,71: 153 – 161.

23. Higaki M., Takase T., Igarashi R. et al. Enhancement of immune response to intranasal influenza HA vaccine by microparticle resin. Vaccine. 1998, 16: 741 – 745.

24. Hoegen P. Synthetic biomimetric supra molecular particles for nasal vaccine delivery. Adv. Drug. Deliv. Rev. 2001, 23: 113 – 125.

25. Illum L., Jabal-Gill I, Ein W. et al. The immune response of nasally administered influenza vaccine is enhanced by the polysaccharide chitosan. Options for the Control of Influenza IV. Crete, Hersonossis, 2000, Abstr. W62 – 3, p. 50.

26. LIlum L., Jabbal-Gill I, Hincheliffe M. et al. Chitozan as novel nasal delivery system for vaccines. Adv. Drug Delivery Rev. 2001, 51: 81 – 96.

27. Johnson P., Feldman S., Thompson J. et al. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold- adapted vaccine, and inactivated vaccine. J. Infect. Dis. 1986,154:121 – 127.

28. Katz J., Eu X., Galphin J. et al. Heat-labile toxin from E.coli as an adjuvant for oral influenza vaccination. Options for the Control of Influenza III. E. Brown, A. Hampson, R. Webster (ed.). Elsevier Sci. 1996, p. 290 – 297.

29. Komase K., Tamura S. Matsuo K. et al. Mutants of E.coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine. Vaccine. 1998, 16: 348- 354.

30. Levine M., Kaper J., Black R. etal. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 1983, 47: 510 – 550.

31. McKenzie S., Halsey J. Cholera toxin В subunit as a carrier protein to stimulate a mucosal immune response. J. Immunol. 1984, 133: 1818 – 1824.

32. Ohlsson B., Duncan J., Mestecky J. et al. Mucosal immunization against influenza virus using bioadhesive polymers. Options for the Control of Influenza. E. Brown, A. Hampson, R. Webster (ed.). Elsevier Sci. 1996, p. 271 – 277.

33. Oplinger M., Baqar S., Trofa A. et al. Safety and immunogenicity in volunteers of a new candidate oral mucosal adjuvant, ET(R1926). Interscience Conference on Antimicrobial Agents and Chemoterap. 1997, Abstr. 6 – 10, p. 193.

34. Plante M., Jones D., Allard F. et al. Nasalproteosome subunit flu vaccine elicits enhance mucosal IgA, serum HAI and protection comparable to conventional injectable flu vaccine. Options for the control of Influenza IV. A. Osterhaus, N. Cox, A. Hampson (ed.). Excerta Med. 2001, p. 979 – 984.

35. Plante M., Jones D., Allard F. et al. Nasal immunization with subunit proteosome influenza vaccine induces serum HAI, mucosal IgA and protection against influenza challenge. Vaccine. 2002, 20: 218 – 225.

36. Rudenko E., Slepushkin A., Monto A. et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J. Infect. Dis. 1993, 168: 881 – 887.

37. Sjolander S., Drane D., Davis R. et al. Intranasal immunization with influenza IS COM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte response. Vaccine. 2000, 16: 4072 – 4080.

38. Tamura S., Funato H., Nagamine T. et al. Effectiveness of cholera toxin В subunit as an adjuvant for nasal influenza vaccination despite pre-exicting immunity to CTB. Ibid. 1989, 7: 503 – 505.

39. Tamura S., Asanuma H., Ito Y. et al. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza HA vaccine. Eur. J. Immunol. 1992, 22: 477 – 481.

40. Tamura S., Ito Y., Asanuma H. et al. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intransally with cholera toxin B subunit. J. Immunol. 1992, 149: 981 – 988.

41. Tamura S., Asanuma H., Tomita T. et al. E.coli heat-labile enterotoxin В subunit supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine. Vaccine. 1994, 12: 1083 – 1089.

42. Tamura S., Kurata T. A proposal for safety standards for human use of cholera toxin (or E.coli heat-labile enterotoxin) derivates as an adjuvant of nasal inactivated influenza vaccine. Jpn. J. Infect. Dis. 2000, 53: 98 – 106.

43. Tumpey T., Renshaw M., Clements J. et al. Mucosal delivery of inactivated influenza vaccine induces B-cel-dependent heterosubtypic cross- protection against lethal influenza A H5N1 virus infection. J. Virol. 2000, 75: 5141 -5150.

44. Tumpey T., Clements J., Katz J. Mucosal vaccination protects mice against influenza A heterosubtypic challenge. Options for Control of Influenza IV. A. Osterhaus, N. Cox, A. Hampson (ed.). Excerpta Med. 2001, p. 985 – 992.

45. Verweij W., De Haan L., Holtrop A. et al. Mucosal immunoadjuvant activity of the recombinant E.coli heat-labile enterotoxin and its В subunit: induction of systemic IgG and secretory IgA response in mice by intranasal immunization with influenza surface antigen. Vaccine. 1998, 20: 2069 – 2076.

46. Wyde P., Guzman E., Gilbert B. et al. Immunogenicity and protection in mice given inactivated influenza vaccine, MPE, QS-21 or QS-7. Options for the Control of Influenza IV. A. Osterhaus, N. Cox, A. Hampson (ed.). Excerpta Med., 2001, p. 999 – 1005.

Author: Site Editor

Share This Post On

Оставить комментарий

Ваш e-mail не будет опубликован. Обязательные поля помечены *